COST-EFFECTIVENESS ANALYSIS OF RAPID MULTIPLEX PCR PANEL FOR SEPSIS DIAGNOSIS IN ICU PATIENTS: VERTICALLY PRIVATE PLAN IN BRAZIL
Author(s)
Gabriel Ogata, MSc1, Ruan Fernandes, MsC2, Henrique Souto Chagas, PharmD3, Juliana Ortega, Msc, PhD4.
1Market Access Manager, Biomerieux, São Paulo, Brazil, 2Biomerieux, Sao Paulo, Brazil, 3Biomerieux, Belo Horizonte, Brazil, 4bioMerieux, Sao Paulo, Brazil.
1Market Access Manager, Biomerieux, São Paulo, Brazil, 2Biomerieux, Sao Paulo, Brazil, 3Biomerieux, Belo Horizonte, Brazil, 4bioMerieux, Sao Paulo, Brazil.
OBJECTIVES: To assess the cost-effectiveness of rapid multiplex PCR panel added to conventional blood culture (CC) versus CC alone for the microbiological diagnosis of sepsis in ICU patients, from the perspective of a vertically health private plan in Brazil
METHODS: A decision-tree model with a 30-day time horizon compared rmPCR plus conventional culture versus conventional culture alone in adult ICU patients with suspected sepsis or bloodstream infection and positive blood cultures. The analysis adopted a vertically integrated private operator perspective, capturing diagnostic and antimicrobial treatment costs. Effectiveness outcomes were hours of empirical antimicrobial therapy avoided and probability of survival. Clinical parameters were derived from a systematic review and meta-analysis of seven studies evaluating the BioFire® BCID2 panel (pooled mortality RR: 0.62; 95% CI: 0.42-0.93; reduction in empirical antimicrobial exposure: -41.77 hours; 95% CI: -60.68 to -22.86). Costs were obtained from CBHPM (2024-2025) and CMED databases. Deterministic and probabilistic sensitivity analyses (PSA, 1,000 simulations) were conducted.
RESULTS: rmPCR plus conventional culture was dominant, reducing empirical antimicrobial therapy by 38.50 hours and increasing survival probability by 18%, while generating cost savings of R$31.81 per patient (total cost: R$6,448.30 vs. R$6,480.11). The ICER was R-0.83perempiricaltreatment−houravoidedandR-0.83 per empirical treatment-hour avoided and R -0.83perempiricaltreatment−houravoidedandR-175.74 per additional survivor. PSA confirmed robustness across 1,000 simulations. A five-year budget impact analysis projected accumulated savings of R$262,967, with increasing efficiency as adoption expanded from 5% to 25% of eligible patients annually.
CONCLUSIONS: From a vertically integrated private operator perspective in Brazil, rmPCR added to conventional culture is cost-saving for sepsis diagnosis in ICU patients, reducing empirical antimicrobial exposure, lowering mortality risk, and supporting antimicrobial stewardship programs in integrated care networks.
METHODS: A decision-tree model with a 30-day time horizon compared rmPCR plus conventional culture versus conventional culture alone in adult ICU patients with suspected sepsis or bloodstream infection and positive blood cultures. The analysis adopted a vertically integrated private operator perspective, capturing diagnostic and antimicrobial treatment costs. Effectiveness outcomes were hours of empirical antimicrobial therapy avoided and probability of survival. Clinical parameters were derived from a systematic review and meta-analysis of seven studies evaluating the BioFire® BCID2 panel (pooled mortality RR: 0.62; 95% CI: 0.42-0.93; reduction in empirical antimicrobial exposure: -41.77 hours; 95% CI: -60.68 to -22.86). Costs were obtained from CBHPM (2024-2025) and CMED databases. Deterministic and probabilistic sensitivity analyses (PSA, 1,000 simulations) were conducted.
RESULTS: rmPCR plus conventional culture was dominant, reducing empirical antimicrobial therapy by 38.50 hours and increasing survival probability by 18%, while generating cost savings of R$31.81 per patient (total cost: R$6,448.30 vs. R$6,480.11). The ICER was R-0.83perempiricaltreatment−houravoidedandR-0.83 per empirical treatment-hour avoided and R -0.83perempiricaltreatment−houravoidedandR-175.74 per additional survivor. PSA confirmed robustness across 1,000 simulations. A five-year budget impact analysis projected accumulated savings of R$262,967, with increasing efficiency as adoption expanded from 5% to 25% of eligible patients annually.
CONCLUSIONS: From a vertically integrated private operator perspective in Brazil, rmPCR added to conventional culture is cost-saving for sepsis diagnosis in ICU patients, reducing empirical antimicrobial exposure, lowering mortality risk, and supporting antimicrobial stewardship programs in integrated care networks.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE644
Topic
Economic Evaluation, Health Technology Assessment, Organizational Practices
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Infectious Disease (non-vaccine)